1. Home
  2. AZTR vs CISS Comparison

AZTR vs CISS Comparison

Compare AZTR & CISS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.24

Market Cap

1.9M

Sector

Health Care

ML Signal

HOLD

Logo C3is Inc.

CISS

C3is Inc.

HOLD

Current Price

$0.80

Market Cap

1.9M

ML Signal

HOLD

Company Overview

Basic Information
Metric
AZTR
CISS
Founded
2014
2022
Country
United States
Greece
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.9M
1.9M
IPO Year
2023
2022

Fundamental Metrics

Financial Performance
Metric
AZTR
CISS
Price
$0.24
$0.80
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$4.00
N/A
AVG Volume (30 Days)
20.5M
669.3K
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
5.06
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
$0.82
Revenue Growth
N/A
N/A
52 Week Low
$0.10
$0.08
52 Week High
$1.40
$5.93

Technical Indicators

Market Signals
Indicator
AZTR
CISS
Relative Strength Index (RSI) 56.72 36.33
Support Level $0.14 $0.75
Resistance Level $0.25 $3.77
Average True Range (ATR) 0.04 0.12
MACD 0.01 -0.02
Stochastic Oscillator 50.91 13.28

Price Performance

Historical Comparison
AZTR
CISS

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

About CISS C3is Inc.

C3is Inc is a provider of international seaborne transportation services to dry bulk charterers, including major national and private industrial users, commodity producers and traders. The company owns and operates a fleet of two dry bulk carriers that transport major bulks such as iron ore, coal and grains, and minor bulks such as bauxite, phosphate and fertilizers. The total cargo-carrying capacity of its fleet is approximately 64,000 dwt.

Share on Social Networks: